Growth Hormone Deficiency Global Market Report 2025

The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of strategic initiatives, increasing incidences of brain tumors, growing demand for hormone therapies, increased elderly population, and rising government funding for healthcare.

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the increasing prevalence of genetic disorders, the rising number of strategic initiatives, enhanced research and development efforts, the growing morbidity of Gh disease, and the expanding number of clinical trials. Key trends in the forecast period include technological advancements, the expansion of treatment options, improvements in diagnostic techniques, recent developments, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the expansion of the growth hormone deficiency market. Genetic disorders are medical conditions resulting from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Several factors contribute to their rising prevalence, including advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency treatments help manage growth-related complications associated with certain genetic conditions. For instance, according to a report published in December 2022 by the Department of Health & Social Care (DHSC), a UK-based government department, approximately 33,000 whole genome equivalents were sequenced in October 2022, with an average diagnostic yield of 32%, rising to 61% in specific conditions. As a result, the increasing prevalence of genetic disorders is fueling the growth of the growth hormone deficiency market.

Leading companies in the growth hormone deficiency market are focusing on developing innovative treatments, such as unmodified somatropin, for pediatric growth hormone deficiency (GHD). Unmodified somatropin is the same growth hormone used in daily GHD treatments but formulated for once-weekly administration with Skytrofa. For example, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched SKYTROFA (lonapegsomatropin) as a once-weekly treatment for pediatric GHD. This innovation enhances convenience, improves adherence, and offers potentially better treatment outcomes compared to traditional daily growth hormone therapies. As the first and only FDA-approved once-weekly treatment for pediatric GHD, it represents a significant advancement in endocrinology and pediatric care.

In February 2022, Pfizer Inc., a US-based pharmaceutical company, partnered with OPKO Health Inc. to advance the treatment of pediatric growth hormone deficiency (GHD). Through this collaboration, Pfizer and OPKO Health aim to develop and commercialize NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone that reduces the injection frequency from once daily to once weekly. This approach improves treatment adherence, minimizes the burden of disease management, and enhances the overall quality of life for children and adolescents with GHD. OPKO Health Inc. is a US-based company specializing in the development and commercialization of treatments for growth hormone deficiency.

Major players in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.

The primary types of growth hormone deficiency are pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency focuses on children with inadequate growth hormone production, resulting in stunted growth and delayed development. Treatments involved are pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. The various routes of administration include intravenous, intramuscular, and others. They are distributed through several channels, such as hospital pharmacy, online pharmacy, and retail pharmacy, and are used by multiple end users, including hospitals, home care, specialty clinics, and others.

The growth hormone deficiency market research report is one of a series of new reports that provides growth hormone deficiency market statistics, including the growth hormone deficiency industry global market size, regional shares, competitors with the growth hormone deficiency market share, detailed growth hormone deficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. This growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.